Document Detail


Danshensu has anti-tumor activity in B16F10 melanoma by inhibiting angiogenesis and tumor cell invasion.
MedLine Citation:
PMID:  20621088     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Danshensu, the major water-soluble component of Radix Salviae Miltiorrhizae (Danshen), is the basic chemical structure of various salvianolic acids. This study was to evaluate the anti-tumor activity of danshensu in a series of in vitro and in vivo models. The effect of danshensu on B16F10 melanoma cell and HUVEC proliferation were assessed by MTS assay, and cell invasion and migration were investigated by transwell chamber assay. The effect of danshensu on angiogenesis was evaluated by HUVEC migration assay, tube formation assay and chick chorioallantoic membrane assay. The expression of MMP-2, -9 and VEGF in B16F10 melanoma cell were detected by western blotting after danshensu treatment. The role of danshensu in tumor metastasis in vivo was evaluated by spontaneous and experimental B16F10 melanoma metastasis model. Although danshensu had no inhibitory effect on B16F10 melanoma cell and HUVEC proliferation, it significantly inhibited B16F10 melanoma cell invasion (at 0.05, 0.5, 5 microM) and migration (at 0.5, 5 microM). It also dramatically suppressed VEGF-induced endothelial migration (at 0.5, 5 microM), tube formation in vitro (at 4, 20 microM) and new vessel formation in CAM in vivo (100 microg/egg). Danshensu (at 5, 50 microM) significantly down-regulates protein expression of MMP-2, -9 and VEGF in B16F10 melanoma cell. In animal model, danshensu (20, 40 mg/kg) also possessed inhibitory effect on lung metastasis in spontaneous (46-day treatment) and experimental (23-day treatment) B16F10 melanoma metastasis model. All these results suggest that danshensu has anti-tumor activity by affecting on tumor angiogenesis and tumor invasion.
Authors:
Li-juan Zhang; Lei Chen; Yin Lu; Jia-ming Wu; Bo Xu; Zhi-guang Sun; Shi-zhong Zheng; Ai-yun Wang
Related Documents :
20129788 - Gamma knife stereotactic radiosurgery yields good long-term outcomes for low-volume uve...
17342328 - Significance of glutathione s-transferases m1, t1 and p1 polymorphisms in swedish melan...
8759358 - Membrane-bound regulators of complement activation in uveal melanomas. cd46, cd55, and ...
10806798 - Expression of the tumor metastatic suppressor gene in mouse melanoma model: inverse ass...
12738098 - Neuroma of the clitoris after female genital cutting.
18937598 - Individualized medicine for renal cell carcinoma: establishment of primary cell line cu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-07-11
Journal Detail:
Title:  European journal of pharmacology     Volume:  643     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-02     Completed Date:  2010-12-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  195-201     Citation Subset:  IM    
Copyright Information:
2010 Elsevier B.V. All rights reserved.
Affiliation:
Department of Clinical Pharmacy, College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / pharmacology,  therapeutic use
Animals
Antineoplastic Agents, Phytogenic / pharmacology*,  therapeutic use*
Cell Movement / drug effects
Cells, Cultured
Chick Embryo
Chorioallantoic Membrane / blood supply,  drug effects
Dose-Response Relationship, Drug
Down-Regulation / drug effects
Endothelial Cells / drug effects
Female
Humans
Lactates / pharmacology*,  therapeutic use*
Lung Neoplasms / prevention & control,  secondary
Matrix Metalloproteinases, Secreted / metabolism
Melanoma, Experimental / drug therapy*,  secondary
Mice
Mice, Inbred C57BL
Neoplasm Invasiveness / prevention & control
Neovascularization, Pathologic / prevention & control*
Osmolar Concentration
Tumor Burden / drug effects
Vascular Endothelial Growth Factors / metabolism
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents, Phytogenic; 0/Lactates; 0/Vascular Endothelial Growth Factors; 23028-17-3/3,4-dihydroxyphenyllactic acid; EC 3.4.24.-/Matrix Metalloproteinases, Secreted

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Angiostatins decrease in the kidney of newborn piglets after hypoxia-reoxygenation.
Next Document:  Antinociceptive effect of butyl (2-phenylethynyl) selenide on formalin test in mice: Evidences for t...